



IBA Announces Formal Contract Signature and Fully Approved Financing for Installation of the Texas Center For Proton Therapy

Louvain-la-Neuve, Belgium, December 21, 2012 - IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce it has signed a formal contract with the Texas Center for Proton Therapy on Wednesday December 12, 2012 for the installation of a multi-room proton therapy system to equip its new facility in Irving-Las Colinas, Texas. The new proton therapy center is a collaborative effort between Dallas-based Texas Oncology, The US Oncology Network supported by McKesson Specialty Health and Baylor Health Enterprises, an affiliate of Baylor Health Care System.

The project is worth an estimated \$50 million to IBA and project financing is fully secured. On top of this, a five years operation and maintenance contract has also been signed. It is expected that the center will open in late 2015.

Full details of the project can be found in the September 7, 2012 press release at <http://group.iba-worldwide.com/news-and-press>

- Ends -

About Proton Therapy

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world's clinically based proton therapy facilities. To date they include 13 operational proton therapy centers worldwide, and 11 more centers in development.

About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.



Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact

IBA

Jean-Marc Bothy

Chief Financial Officer

Tel: +32 10 47 58 90

Thomas Ralet

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com

For media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson

+44 (0) 207 920 2333

IBA@mcomgroup.com